Entering text into the input field will update the search result below

Bard Q3 top line up 9%; non-GAAP EPS up 16%

Oct. 25, 2016 5:12 PM ETC. R. Bard, Inc. (BCR) StockBy: Douglas W. House, SA News Editor1 Comment
  • C.R. Bard (NYSE:BCR) Q3 results ($M): Total Revenues: 941.9 (+8.8%); Vascular: 258.1 (+3.0%); Urology: 242.1 (+14.0%); Oncology: 258.4 (+8.0%); Surgical Specialties: 158.8 (+13.6%).
  • Net Income: 96.4 (+212.1%); Non-GAAP Net Income: 199.5 (+14.2%); EPS: 1.27 (+209.5%); Non-GAAP EPS: 2.64 (+15.8%).
  • 2016 Guidance: Revenue Growth: 8 - 9%; Non-GAAP EPS: $10.23 - 10.28.
  • Q3 revenues were 1.1% above consensus of $931.7M and non-GAAP EPS was 3.5% above consensus of $2.55.
  • Q4 consensus is non-GAAP EPS of $2.74 on revenues of $943.4M.

Recommended For You

Related Stocks

SymbolLast Price% Chg
BCR--
C. R. Bard, Inc.